Condition: Primary Mediastinal Large B-cell Lymphoma · Sponsor: Centre Henri Becquerel
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving standard R-CHOP14 or R-ACVBP.
This description comes directly from the study's public registry record.
VINCENT CAMUS, MD · +33232082497 · vincent.camus@chb.unicancer.fr
RICHARD DORIANE, PhD · +33232082985 · doriane.richard@chb.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Lyon Sud | Lyon, France | Not Yet Recruiting |
| Centre Henri Becquerel | Rouen, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04824950